RNAi Oligonucleotides Targeting HNRNPH2 Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no effective therapy or cure for Bain Syndrome, a condition caused by mutations in the HNRNPH2 gene that leads to toxic protein accumulation, resulting in severe developmental and behavioral issues, with existing therapeutic approaches being inadequate.
Innovation Solution
Development of novel RNA-targeting oligonucleotides, including siRNA and shRNA, that specifically reduce the expression of toxic HNRNPH2 alleles by targeting missense mutations and wild-type HNRNPH2, using adeno-associated viral and lentiviral vectors for delivery, to mitigate the disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If allele-specific RNAi is used to target mutant HNRNPH2 variants, then selective reduction of toxic mutant protein is achieved, but differentiation between mutant and wild-type alleles becomes challenging
Solution Approach 1:
The patent applies local quality by designing siRNA sequences that target specific local regions (mutation sites) within the HNRNPH2 mRNA. By focusing the RNAi mechanism on the precise location of missense mutations (e.g., Arg206Trp, Arg206Gln, Pro209Leu), the therapy achieves selective reduction of mutant alleles without affecting wild-type HNRNPH2, resolving the contradiction between selectivity and complexity
Solution Approach 2:
The patent segments the HNRNPH2 gene target into multiple distinct siRNA sequences, each designed to recognize specific mutant variants. This segmentation allows individual siRNAs to be optimized for particular mutations (Arg206Trp, Arg206Gln, Pro209Leu), enabling selective targeting of different mutant alleles while maintaining simplicity in the overall therapeutic approach
2Object-generated harmful factors
If complete knockdown of HNRNPH2 is achieved, then toxic mutant protein production is eliminated, but potential loss of normal HNRNPH2 function may occur
Solution Approach 1:
The patent converts the harmful effect of mutant HNRNPH2 accumulation into a beneficial therapeutic outcome by using RNAi to selectively silence only the mutant alleles. The approach exploits the presence of missense mutations as unique targets, transforming what was previously a pathological feature (mutation) into the basis for selective therapy, thereby eliminating toxic protein while preserving wild-type function
Solution Approach 2:
The patent changes the parameter of gene expression specificity by designing siRNA sequences with precise complementarity to mutant HNRNPH2 mRNA. By adjusting the degree of sequence matching to target only mutant variants with specific nucleotide changes, the therapy reduces mutant protein levels while maintaining normal HNRNPH2 expression, resolving the contradiction between eliminating harm and preserving function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAi oligonucleotides effectively inhibit mutant HNRNPH2 production without affecting non-mutant HNRNPH2, potentially providing a therapeutic avenue for Bain Syndrome by reducing mutant protein levels, thereby alleviating associated symptoms.
Implementation Method 1
RNAi involving siRNA and shRNA that reduce expression of toxic HNRNPH2 alleles thereby reducing production of mutant HNRNPH2
Implementation Method 2
siRNAs targeting individual HNRNPH2 missense mutations including a nucleotide sequence that is at least 85%, at least 90%, at least 95%, or 100% complementary to any of SEQ ID NOs: 1-18 and 25-42
Data Source
AI summary
RNAi involving siRNA or shRNA is provided that reduces expression of toxic HNRNPH2 alleles containing one or more R206W, R206Q and P209L missense mutations thereby reducing production of mutant HNRNPH2 for treatment of Bain Syndrome. RNAi involving siRNA or shRNA is provided that reduces expression of wild-type HNRNPH2 thereby reducing production of HNRNPH2 for treatment of Bain Syndrome.